Results 121 to 130 of about 1,343 (193)

Psychedelics: preclinical insights provide directions for future research. [PDF]

Neuropsychopharmacology
Gumpper RH, Roth BL.
europepmc   +1 more source

Reconsideration of Surgical Indication for Prolactin-producing Pituitary Tumor Focusing on Visual Impairment. [PDF]

Neurol Med Chir (Tokyo)
Amano K, Oda Y, Seki Y, Yamashita K, Bokuda K, Ichihara A, Kawamata T.   +6 more
europepmc   +1 more source

Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center. [PDF]

Pituitary
Prencipe N, Bona C, Cuboni D, Berton AM, Bioletto F, Varaldo E, Aversa LS, Sibilla M, Gasco V, Ghigo E, Grottoli S.   +10 more
europepmc   +1 more source

Ethical Considerations Regarding Psychedelics for Clinical Pain Research. [PDF]

J Pain Res
Robinson CL, Slitzky M, Schatman ME, Yong RJ, Lehman AD, Kaynar AM, Shivanekar SP, Emerick T.   +7 more
europepmc   +1 more source

Licit use of illicit drugs for treating depression: the pill and the process. [PDF]

J Clin Invest
Torrado Pacheco A, Moghaddam B.
europepmc   +1 more source

Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial. [PDF]

PLoS One
Hjelholt AJ, Bach FW, Kasch H, Støvring H, Jensen TS, Jørgensen JOL.   +5 more
europepmc   +1 more source

Psychedelics: Safety and Efficacy. [PDF]

Int J Environ Res Public Health
Miller N.
europepmc   +1 more source

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. [PDF]

Neuropsychopharmacology
Mitchell JM, Anderson BT.
europepmc   +1 more source

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money. [PDF]

Annu Rev Psychol
Humphreys K, Todd Korthuis P, Stjepanović D, Hall W.   +3 more
europepmc   +1 more source